Intellia Therapeutics NTLA Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's other income (expense)?
- Intellia Therapeutics (NTLA) reported other income (expense) of $4.3M in Q1 2026.
- How has Intellia Therapeutics's other income (expense) changed year-over-year?
- Intellia Therapeutics's other income (expense) decreased by 33.6% year-over-year, from $6.48M to $4.3M.
- What is the long-term trend for Intellia Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), Intellia Therapeutics's other income (expense) has grown at a 409.5% compound annual growth rate (CAGR), from -$42K to $28.3M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.